Drugs / dilmapimod
dilmapimod
also known as
SB-681323 · [14C]SB-681323 · Dilmapimod tosilate · DILMAPIMOD TOSYLATE · Gw-681323 · SB-681323-T
Small molecule targets MAPK14 via inhibition
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT00564746 | Sep → Oct 2007 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00439881 | Oct 2006 → ? | rheumatoid arthritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00380133 | Jun 2005 → Apr 2006 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00419809 | May → Dec 2005 | rheumatoid arthritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT00996840 | Oct 2009 → Feb 2013 | acute lung injury | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00390845 | Aug 2006 → Aug 2008 | neuropathy, painful | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00291902 | Mar 2006 → ? | coronary artery disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00320450 | Nov 2005 → Oct 2006 | rheumatoid arthritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00144859 | Jul 2005 → ? | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00134693 | Jun 2005 → Aug 2006 | rheumatoid arthritis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dilmapimod | “The novel p38 mitogen-activated protein kinase inhibitor dilmapimod appears well tolerated and may merit further evaluation for prevention of acute respiratory distress...” PMID 26102252 ↗ Sep 2015 |
| Known as | [14C]SB-681323 | “A single 10 milligram (50 microcurie) oral dose of [14C]SB-681323” NCT00564746 ↗ |
| Known as | Dilmapimod tosilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103838 ↗ |
| Known as | DILMAPIMOD TOSYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103838 ↗ |
| Known as | Gw-681323 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103838 ↗ |
| Known as | SB-681323 | “A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients.” PMID 19880675 ↗ Oct 200911“P38 Mitogen-activated Protein (Map) Kinase Inhibitor (SB-681323)Study In Patients With Neuropathic Pain” NCT00390845 ↗ |
| Known as | SB-681323-T | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103838 ↗ |
| Action | Inhibit | “a p38α/β mitogen-activated protein kinase inhibitor, SB-681323” PMID 20689074 ↗ Aug 20101“MAP kinase p38 alpha inhibitor” CHEMBL2103838 ↗ |
| Modality | Small molecule | “p38 MAP kinase inhibitor” NCT00564746 ↗ |
| Route | Oral | “Single Oral Doses of SB-681323 (7.5 mg and 25 mg) and Prednisolone (10 mg and 30 mg)” NCT00380133 ↗ |
| Target | MAPK14 | “MAP kinase p38 alpha inhibitor” CHEMBL2103838 ↗ |